Protagonist Therapeutics: Pay

Protagonist Therapeutics paid its 3 named executives $20.2M in total in FY2025 (Dec). CEO Dinesh V. Patel, Ph.D. was paid $12.9M of that.

Pay$100 in the stock at the end of FY21 → $255
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Dinesh V. Patel, Ph.D.President and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Arturo Molina, M.D., M.S., F.A.C.P.Chief Medical Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Asif AliEVP, Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 4 peers with pay on file was $10.7M. The CEO of Protagonist Therapeutics was paid $12.9M, 20% above the median.

  1. 1Viking Therapeutics
  2. 2Protagonist Therapeutics
  3. 3Cytokinetics
  4. 4IDEAYA Biosciences
  5. 5Agios Pharmaceuticals
  6. 6Akero Therapeutics, Inc.Not disclosed
  7. 7Arcellx, Inc.Not disclosed
  8. 8Biohaven, Ltd.Not disclosed
  9. 9Celldex Therapeutics, Inc.Not disclosed
  10. 10Crinetics Pharmaceuticals, Inc.Not disclosed
  11. 11Denali Therapeutics, Inc.Not disclosed
  12. 12Disc Medicine, Inc.Not disclosed
  13. 13Geron CorporationNot disclosed
  14. 14Immunovant, Inc.Not disclosed
  15. 15Keros Therapeutics, Inc.Not disclosed
  16. 16Kura Oncology, Inc.Not disclosed
  17. 17Nurix Therapeutics, Inc.Not disclosed
  18. 18Rhythm PharmaceuticalsNot disclosed
  19. 19Structure Therapeutics, Inc.Not disclosed
  20. 20Syndax Pharmaceuticals, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.